Elanco Receives FDA Approval for Credelio Quattro™, the Broadest Canine Oral Parasiticide Protection in a Single Monthly Dose
Elanco Animal Health Incorporated (NYSE: ELAN) announced the U.S. Food and Drug Administration (FDA) has approved Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), becoming the broadest approved canine oral parasiticide with its protection against six types of parasites—fleas, ticks, heartworms, and the three risky intestinal parasites—roundworms, hookworms and tapeworms. Credelio Quattro is a single, monthly chewable tablet for dogs eight weeks of age or older.
“Today is another milestone in Elanco’s historic era of innovation, with the third of three approvals for blockbuster potential products in the U.S. this year. More importantly, we’re bringing veterinarians and pet owners the broadest parasite protection by covering six types of parasites in a monthly chewable tablet,” said Jeff Simmons, President and CEO, Elanco Animal Health. “As pets have become such an integral part of the family, we’re pleased to offer veterinarians and pet owners a first-of-its-kind solution that protects against some of the most dangerous parasites that can spread disease to both pets and people.”
Credelio Quattro is the newest addition to the Credelio®(lotilaner) franchise and the first FDA-approved parasiticide product with four active ingredients. Credelio Quattro:
- Starts to kill ticksv and fleas in just 4 hours.
- Kills >99% of fleas within 8 hours of administration and 100% in the first day and remains effective for an entire month.
- Provided 100% protection from heartworm disease from the first monthly dose in laboratory studies.
- Contains lotilaner that kills ticksvi twice as fastvii as sarolaner in Simparica Trio® and afoxolaner in NexGard®viii.
- Is gentle enough for puppies as small as 3.3 pounds and as young as 8 weeks.
- Comes in a tasty beef-flavored, easy-to-administer chewable.
- Provides coverage against internal parasites with zoonotic potential, meaning parasites that have the potential to infect people as well as pets, including echinococcus tapeworm.
“Zoonotic disease is more common than many might think. One of our own Elanco veterinarians recently found echinococcus tapeworm lurking in her back yard,” said Dr. David Gosche, veterinarian and U.S. Pet Health Medical Director at Elanco. “Zoonotic disease affects millions of people and animals worldwide each year. Our pets can easily serve as the ‘bridge hosts,’ bringing these parasites into our homes when they cuddle with us on couches or in our beds—making it very easy to go from ‘ick’ to ‘sick.’ That’s why we recommend year-round treatment with the broad spectrum parasite protection in Credelio Quattro.”
Credelio Quattro joins Elanco’s broad portfolio of parasiticides, including Seresto® and the Advantage® family, to provide veterinarians and pet owners with an innovative new solution while also offering a wide range of products at a variety of price points where consumers choose to shop. Elanco expects Credelio Quattro to launch in the first quarter of 2025. Learn more about Credelio Quattro at CredelioQuattroVet.com.
Short URL: https://caninechronicle.com/?p=306210
Comments are closed